肝硬化门静脉高压导致的胃肠结构和功能改变及其临床表现

尚祉胤; 杨敬貌; 陈丽萍; 刘敏; 程开; 李耀华; 艾迎春; 程计林

doi:10.3969/j.issn.1001-5256.2017.02.034

肝硬化门静脉高压导致的胃肠结构和功能改变及其临床表现

DOI: 10.3969/j.issn.1001-5256.2017.02.034

1. 佳木斯大学附属第一医院消化科
2. 上海市公共卫生临床中心消化科
3. 温州医科大学
4. 复旦大学上海医学院生物化学与分子生物学系

详细信息

中图分类号: R575.21
计量
- 文章访问数: 2214
- HTML全文浏览量: 31
- PDF下载量: 498
- 被引次数: 0
出版历程
- 收稿日期: 2016-09-13
- 出版日期: 2017-02-20

Changes in gastrointestinal structure and function caused by cirrhotic portal hypertension and related clinical manifestations

Department of Gastroenterology,The First Affiliated Hospital of Jiamusi University

摘要

摘要: 临床上高达80%的肝硬化门静脉高压患者存在不同程度胃肠症状,这与肝硬化门静脉高压导致的胃肠结构改变、胃肠功能失调及神经体液调节改变有关。回顾了肝硬化门静脉高压对胃肠结构改变、胃肠功能失调及神经体液调节改变的影响,以及这些改变所导致的消化道临床表现,提示对肝硬化门静脉高压胃肠结构改变进行研究,可以有效地预防和治疗肝硬化的并发症,改善胃肠症状;另外,对胃肠功能进行调节,可改善患者症状,有助于延缓肝硬化进展,建议定期内窥镜评估肝硬化患者胃肠黏膜和血管的改变,有助于早期治疗和减少并发症。
- 肝硬化 /
- 门静脉压 /
- 胃肠道 /
- 综述
Abstract: In clinical practice,up to 80% of patients with cirrhotic portal hypertension have varying degrees of gastrointestinal symptoms,which are associated with the changes in gastrointestinal structure,gastrointestinal dysfunction,and altered neurohumoral regulation.This article reviews the changes in gastrointestinal structure,gastrointestinal dysfunction,and altered neurohumoral regulation caused by cirrhotic portal hypertension,as well as the gastrointestinal clinical manifestations caused by such changes.It is pointed out that the research on the changes in gastrointestinal structure in cirrhotic patients with portal hypertension helps to effectively prevent and treat the complications of liver cirrhosis and improve gastrointestinal symptoms.In addition,the regulation of gastrointestinal function can improve patients' symptoms and delay the progression of liver cirrhosis.Therefore,it is recommended to regularly evaluate the changes in gastrointestinal mucosa and vessels in patients with liver cirrhosis,in order to provide early treatment and reduce complications.
- liver cirrhosis /
- portal pressure /
- gastrointestinal tract /
- review

HTML全文

参考文献(35)

[1]KALAITZAKIS E.Gastrointestinal dysfunction in liver cirrhosis[J].World J Gastroenterol,2014,20(40):14686-14695.

[2]URRUNAGA NH,ROCKEY DC.Portal hypertensive gastropathy and colopathy[J].Clin Liver Dis,2014,18(2):389-406.

[3]CHUNG WJ.Management of portal hypertensive gastropathy and other bleeding[J].Clin Mol Hepatol,2014,20(1):1-5.

[4]NOJKOV B,CAPPELL MS.Distinctive aspects of peptic ulcer disease,Dieulafoy's lesion,and Mallory-Weiss syndrome in patients with advanced alcoholic liver disease or cirrhosis[J].World J Gastroenterol,2016,22(1):446-466.

[5]MEKAROONKAMOL P,COHEN R,CHAWLA S.Portal hypertensive enteropathy[J].World J Hepatol,2015,7(2):127-138.

[6]JEON SR,KIM JO.Capsule endoscopy for portal hypertensive enteropathy[J].Gastroenterol Res Pract,2016,2016:8501394.

[7]ELAMIN EE,MASCLEE AA,DEKKER J,et al.Ethanol metabolism and its effects on the intestinal epithelial barrier[J].Nutr Rev,2013,71(7):483-499.

[8]AL-BUSAFI SA,McN ABB-BALTAR J,FARAG A,et al.Clinical manifestations of portal hypertension[J].Int J Hepatol,2012,2012:203794.

[9]HOU Y.The clinical comparision of cirrhosis patients with different etiological upper digestive tract hemorrhage[J].J Clin Exp Med,2015,14(12):999-1001.(in Chinese)侯昀.肝硬化不同病因上消化道出血患者的临床对比[J].临床和实验医学杂志,2015,14(12):999-1001.

[10] SHARMA M,RAMESHBABU CS.Collateral pathways in portal hypertension[J].J Clin Exp Hepatol,2012,2(4):338-352.

[11]PILLAI AK,ANDRING B,PATEL A,et al.Portal hypertension:a review of portosystemic collateral pathways and endovascular interventions[J].Clin Radiol,2015,70(10):1047-1059.

[12]KAPOOR A,DHAREL N,SANYAL AJ.Endoscopic diagnosis and therapy in gastroesophageal variceal bleeding[J].Gastrointest Endosc Clin N Am,2015,25(3):491-507.

[13]WU Q,SHEN L,CHU J,et al.Characterization of uncommon portosystemic collateral circulations in patients with hepatic cirrhosis[J].Oncol Lett,2015,9(1):347-350.

[14]QI X,LI H,LIU X,et al.Novel insights into the development of portal vein thrombosis in cirrhosis patients[J].Expert Rev Gastroenterol Hepatol,2015,9(11):1421-1432.

[15]MASTORAKI A,MASTORAKI S,TZIAVA E,et al.Mesenteric ischemia:pathogenesis and challenging diagnostic and therapeutic modalities[J].World J Gastrointest Pathophysiol,2016,7(1):125-130.

[16]NORMAN K,PIRLICH M.Gastrointestinal tract in liver disease:which organ is sick?[J].Curr Opin Clin Nutr Metab Care,2008,11(5):613-619.

[17]DU PLESSIS J,VANHEEL H,JANSSEN CE,et al.Activated intestinal macrophages in patients with cirrhosis release NO and IL-6that may disrupt intestinal barrier function[J].J Hepatol,2013,58(6):1125-1132.

[18]TELTSCHIK Z,WIEST R,BEISNER J,et al.Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense[J].Hepatology,2012,55(4):1154-1163.

[19]ARVANITI V,D'AMICO G,FEDE G,et al.Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J].Gastroenterology,2010,139(4):1246-1256,1256.e1-e5.

[20]FRANCES R,MUNOZ C,ZAPATER P,et al.Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites[J].Gut,2004,53(6):860-864.

[21]KIM BI,KIM HJ,PARK JH,et al.Increased intestinal permeability as a predictor of bacterial infections in patients with decompensated liver cirrhosis and hemorrhage[J].J Gastroenterol Hepatol,2011,26(3):550-557.

[22] SHUKLA S,SHUKLA A,MEHBOOB S,et al.Meta-analysis:the effects of gut flora modulation using prebiotics,probiotics and synbiotics on minimal hepatic encephalopathy[J].Aliment Pharmacol Ther,2011,33(6):662-671.

[23]ALBILLOS A,de LA HERA A,GONZALEZ M,et al.Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement[J].Hepatology,2003,37(1):208-217.

[24]SANDLER NG,KOH C,ROQUE A,et al.Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection[J].Gastroenterology,2011,141(4):1220-1230,1230.e1-e3.

[25]SCHECHTER RB,LEMME EM,COELHO HS.Gastroesophageal reflux in cirrhotic patients with esophageal varices without endoscopic treatment[J].Arq Gastroenterol,2007,44(2):145-150.

[26]ZHANG J,CUI PL,LV D,et al.Gastroesophageal reflux in cirrhotic patients without esophageal varices[J].World J Gastroenterol,2011,17(13):1753-1758.

[27]SHARMA M,RAMESHBABU CS.Collateral pathways in portal hypertension[J].J Clin Exp Hepatol,2012,2(4):338-352.

[28]KALAITZAKIS E,SADIK R,HOLST JJ,et al.Gut transit is associated with gastrointestinal symptoms and gut hormone profile in patients with cirrhosis[J].Clin Gastroenterol Hepatol,2009,7(3):346-352.

[29]CHANDER ROLAND B,GARCIA-TSAO G,CIARLEGLIO MM,et al.Decompensated cirrhotics have slower intestinal transit times as compared with compensated cirrhotics and healthy controls[J].J Clin Gastroenterol,2013,47(10):888-893.

[30]LAVIANO A,CANGIANO C,PREZIOSA I,et al.Plasma tryptophan levels and anorexia in liver cirrhosis[J].Int J Eat Disord,1997,21(2):181-186.

[31]MIYAJIMA H,NOMURA M,MUGURUMA N,et al.Relationship among gastric motility,autonomic activity,and portal hemodynamics in patients with liver cirrhosis[J].J Gastroenterol Hepatol,2001,16(6):647-659.

[32]GAIVORONSKII IV,TIKHONOVA LP,CHEPUR SV,et al.Intramural nervous apparatus of jejunum and rectum in experimental portal hypertension[J].Morfologiia,2004,125(3):36-40.

[33]ZHU JZ,XU QZ,LIU QH.The changes of interstitial cell of Cajal in antrum of rats with liver cirrhosis[J].Chin J Gastroenter Hepatol,2005,14(6):618-620.(in Chinese)朱金照,许其增,刘庆宏.肝硬化大鼠胃窦Cajal间质细胞的变化[J].胃肠病学和肝病学杂志,2005,14(6):618-620.

[34]USAMI A,MIZUKAMI Y,ONJI M.Abnormal gastric motility in liver cirrhosis:roles of secretin[J].Dig Dis Sci,1998,43(11):2392-2397.

[35]TANG XD,FAN H,WAN P,et al.Multiple analysis on the gastric impetus associated factors in patients with liver cirrhosis[J].Chin JHepatol,2004,12(3):141-143.(in Chinese)唐晓丹,范红,万平,等.肝硬化患者胃动力多因素相关性研究[J].中华肝脏病杂志,2004,12(3):141-143.

施引文献

资源附件(0)

访问统计